Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

Trial Profile

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Fimepinostat (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Curis
  • Most Recent Events

    • 12 Dec 2017 Results (n=131; As of 29 June 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Dec 2017 According to a Curis media release, data will be presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 14 Oct 2017 This trial has been completed in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top